



ABSTRACTS

8th International Workshop on Lung Health

Virtual Edition
13–16 January 2021



European Respiratory & Pulmonary Diseases

SUPPLEMENT

www.touchRESPIRATORY.com

European Respiratory & Pulmonary Diseases

Volume 7 • Issue 1 • Supplement 1 • 2021



Cover image: Human lungs by krishnacreations
© stock.adobe.com

Editorial Board

Ian Adcock

Professor of Respiratory Cell and Molecular Biology, Faculty of Medicine, National Heart & Lung Institute, Imperial College London, UK

Andrea Aliverti

Professor of Bioengineering, Department of Electronics, Information and Bioengineering (DEIB), Politecnico di Milano (Polimi), Milan, Italy

Peter Barnes

Margaret Turner-Warwick Professor of Medicine, National Heart and Lung Institute; Head of Respiratory Medicine, Imperial College, London, UK

Pierre Bartsch

Medical Clinic VII, Sports Medicine, University Hospital Heidelberg, Germany

Mario Cazzola

Professor of Respiratory Medicine and Director of the Postgraduate School of Respiratory Medicine, University of Rome 'Tor Vergata', Rome, Italy

Refika Ersu

Division of Paediatric Pulmonology, Marmara University, Istanbul, Turkey

Enrico Heffler

Assistant Professor in Respiratory Medicine and Consultant at the Personalized Medicine, Asthma & Allergy Unit, Humanitas University of Milan, Milan, Italy

Felix Herth

Medical Director, Thoraxklinik, University of Heidelberg, Heidelberg, Germany

Fabio Midulla

University of Rome 'La Sapienza', Rome, Italy

Marc Miravittles

Chest Physician and Senior Researcher, Department of Pneumology, Hospital Universitari Vall d'Hebron, Barcelona, Spain

Mário Morais-Almeida

Specialist in Allergy and Clinical Immunology and on Health Units Management, Head of the Allergy Center of CUF-Descobertas Hospital and CUF-Infante Santo Hospital in Lisbon and Researcher of CINTESIS – Center for Health Technology and Services Research, Porto Medical School, Portugal

Nikolaos Panagiotopoulos

Consultant Thoracic Surgeon, University College London Hospitals UCLH, London, UK

Dave Singh

Professor of Respiratory Pharmacology, University of Manchester, UK

Antonio Spanevello

Director of the Post-Graduate School in Respiratory Diseases, University of Insubria, Varese, Italy

Jean-Pierre Zellweger

Medical Adviser, TB Competence Centre, Swiss Lung Association, Berne, Switzerland

Editorial Director

Nicola Cartridge

Editor

Lisa Glass

Associate Editor

Heather Hall

Design Manager

Julie Stevenson

Editorial

Lisa Glass

E: lisa.glass@touchmedicalmedia.com

T: +44(0)207 193 4749

Group Director

Matthew Goodwin

E: matthew.goodwin@touchmedicalmedia.com

T: +44 (0)20 7193 3968

CEO & Managing Director

Barney Kent

E: barney.kent@touchmedicalmedia.com

T: +44 (0)20 7193 3009

Head of Strategic Partnerships

Caroline Markham

E: caroline.markham@touchmedicalmedia.com

T: +44 (0)20 7193 3704



www.touchmedicalmedia.com

All information obtained by Touch Medical Media and each of the contributors from various sources is as current and accurate as possible. However, due to human or mechanical errors, Touch Medical Media and the contributors cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions, or for the results obtained from the use thereof. Where opinion is expressed, it is that of the authors and does not necessarily coincide with the editorial views of Touch Medical Media. Statistical and financial data in this publication have been compiled on the basis of factual information and do not constitute any investment advertisement or investment advice. For the avoidance of doubt, the information contained in this publication is intended for use by licensed medical professionals. The content should not be considered medical advice, diagnosis or treatment recommendations.

© 2021 Touch Medical Media Limited, trading as Touch Medical Media, is a private limited company registered in England and Wales at The White House, Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. All rights reserved. ISSN 2058-4881



th

INTERNATIONAL WORKSHOP ON LUNG HEALTH

Treatable Traits: a look forward

Presidents:

Francesco Blasi
G. Walter Canonica

Chairmen:

Stefano Aliberti
Stefano Centanni
Johann Christian Virchow
Tobias Welte



VIRTUAL EDITION
13 - 16 JANUARY 2021

Organized by



PCO - Organising Secretariat



Publi Créations

www.lung-health.org

8th International Workshop on Lung Health



Virtual Edition
13–16 January 2021

ABSTRACTS

Presidents

Francesco Blasi, Italy
G Walter Canonica, Italy

Chairmen

Stefano Aliberti, Italy
Stefano Centanni, Italy
Johann Christian Virchow, Germany
Tobias Welte, Germany

Important note:

The abstracts in this book are listed in alphabetical order (first author, last name).

Table. 2. Spirometry indices in the examined patients.

Characteristics	Group I (non-smokers)	Group II (smokers)	p
FVC, % Me [25 %-75 %]	85,0 (77,0-92,0)	87,5(70,0-96,0)	0,8
FEV1, % Me [25 %-75 %]	51,0 (44,0 -62,0)	45,0 (34,0 -59,0)	0,04
FEV1%M Me [25 %-75 %]	54,5 (37,0-65,0)	48,0(54,0- 62,0)	0,3
MEF 75, % Me [25 %-75 %]	53,0 (41,6-68,6)	43,0 (31,3-56,4)	0,6
MEF 50, % Me [25 %-75 %]	19,5 (25,5-51,5)	40,0 (18,7-55,2)	0,2
MEF 25, % Me [25 %-75 %]	22,0 (23,8-48,0)	31,0 (15,4-34,7)	0,6
PEF, % Me [25 %-75 %]	54,5 (37,0-65,0)	50,5 (30,7,0-65,0)	0,5
IC_F, % Me [25 %-75 %]	57,5 (47,2-69,6)	52,5 (17,7-65,0)	0,8

Table. 3. Indicators of nutritional status in the examined patients with COPD.

Characteristics	Group I (non-smokers)	Group II (smokers)	p
Age, y M(SD)	55,8 (6,7)	58,3 (8,1)	0,1
Body mass , kg Me [25 %-75 %]	87,0 (82,0-88,0)	78,0(71,7-93,3)	0,7
BMI, Me [25 %-75 %]	26,3(25,0-30,0)	26,6(23,9-30,3)	0,9
Fat tissue, % Me [25 %-75 %]	25,05(24,6- 25,1)	35,1(31,1-37,5)	0,001
Muscle tissue , % Me [25 %-75 %]	39,9(34,5-44,9)	20,8 (16,8-29,7)	0,002
Visceral fat , % Me [25 %-75 %]	10,5 (8,0-12,0)	8,0 (5,5-11,0)	0,2
Waist circumference , sm M(SD)	95,5 (1,5)	91,5 (1,7)	0,3

Conclusions: Patients suffering from COPD have a violation of nutritional status. Smoking patients develop sarcopenic obesity, which progresses with an increase in the degree of nicotine addiction, correlates with the “pack / year” index and is a predictor of increased mortality in this category of patients. Increased bronchial obstruction in smokers with COPD is observed with an increase in smoking history, the number of cigarettes smoked and with a decrease in body weight. Reducing the pool of muscle tissue can be considered as an early predictor of more frequent exacerbations in smoking patients with COPD. □

The features of frequent exacerbators phenotype in patients with bronchiectasis in Ukraine

Kateryna Gashynova¹; Kseniia Suska¹; Valeriia Dmytrychenko¹

¹Dnipropetrovsk Medical Academy, Dnipro, Ukraine

Background: Exacerbations are the key predictors of the progression of bronchiectasis and mortality rising. Traditionally, the presence of *Pseudomonas aeruginosa* in sputum, underweight, low pulmonary function and previous hospitalizations are predictors of more frequent exacerbations. The objective was to determine if there are other factors of more frequent exacerbations in patients with bronchiectasis in Dnipro region of Ukraine.

Materials and methods: 76 patients with confirmed bronchiectasis by HRCT were included. Exacerbations frequency during the previous year was calculated by medical documentation analyzing. Microbiological detection of sputum samples was conducted by conventional bacteriological methods. Weight and visceral fat (VF) were measured by «Body composition monitor Omron BF511» for the static weighing and body mass index (BMI) was calculated. The methods of descriptive and non-parametric statistics were used to process the results.

Results: The median age was 56(38.5:65.5) years, 25 were men (32.9%). 39 patients (51.3%) had 0-2 exacerbations in previous year and were

included in G1. 37 patients (48.7%) had 3 and more exacerbations per previous year (frequent exacerbators) and were included in G2 for analysis. The median BMI in G1 was 22.3(20.4;25.1)kg/m², in G2 – 26(21.6;28.4)kg/m², p=0.028. According to the results of the BMI calculation, the patients in were distributed as follows: in G1 underweight (≤ 18.5 kg/m²) – 2 (5.1%) patients, in G2 – 4 (10.8%), p=0.56; normal weight (18.5-25 kg/m²) in G1 – 26 (66.7%), in G2 – 12 (32.4%), p=0.006; overweight (25<BMI \leq 30 kg/m²) in G1 – 11 (28.2%), in G2 – 21 (56.8%), p=0.012; obesity class I (30<BMI \leq 35 kg/m²) in G1 had 3 (7.7%) patients, in G2 – 7 (18.9%), p=0.06. The median VF in G1 was 5(4;9)%, in G2 – 9(5;13)%, p=0.039. Asthma was a comorbid condition in 12 patients in the group of frequent exacerbators (32.4%), while no one patient from G1 had comorbid asthma, p=0.0001. 8 patients from 12 (66.7%) with asthma in G2 also had an overweight, the median BMI was 26(22;30.5) kg/m², the median exacerbation frequency was 4(3;7.5) per year.

Conclusions: Almost half of patients with bronchiectasis in Ukraine are frequent exacerbators. Based on the data received it is possible to assume that high percentage of VF and overweight in general could be factors which lead to more frequent exacerbation in patients with bronchiectasis in Ukraine even more than underweight. In turn, the presence of comorbid asthma also is one of the predictor of more frequent exacerbations. This indicates the need for lifestyle modifications to correct BMI in order to reduce the number of exacerbations. Patients with comorbid asthma and overweight require special attention to predict further high exacerbations frequency. □

COPD: Alfa-1 antitrypsin (AAT) serum concentration and the airway obstruction

Kateryna Gashynova¹

¹SE «DMA», Dnipro, Ukraine

AAT hereditary deficiency is proved risk factor for COPD. However, only 1 % of patients (pts) with COPD have genetically determined AAT deficiency.

Aim: to evaluate serum AAT in pts with stable COPD and study whether severity of airway obstruction depends on the serum AAT concentration. Study population. Stable pts with confirmed COPD (GOLD I-IV). Exclusion criteria were gastrointestinal comorbidity, malignancy, systemic connective tissue diseases and any signs of acute inflammation.

Methods: AE history during past year, post-bronchodilator spirometry (by Masterlab, Viasis), serum AAT (by kinetic immune turbidimetry) were evaluated in all pts.

Results: 45 stable patients (pts) with COPD (GOLD I-IV) (41 (91%) men) made the study sample. Medium AAT serum concentration were within normal ranges (189,54 [147.60-209.24] mg/dl). However, in 9 pts (20 %) AAT concentration was low (under 150 mg/dl) and in 6 pts (13 %) it was borderline (150-160 mg/dl).

The difference in AAT was statistically significant in groups with different GOLD stages (p = 0.009). FEV1 positively moderately correlate with serum AAT concentration (R = 0.415, p = 0.006).

Conclusion:

- 20 % of pts with stable COPD have low serum AAT concentration despite normal genetic profile.
- Serum AAT concentration negatively correlate with severity of airflow limitation □

Hypodiagnosis of Primary antibody deficiencies in patients with COPD, Sarcoidosis and Chronic Rhinosinusitis

Ourlana Koltsida²; G Tsiouma³; G Tsinti³; S Tryfon⁴; Zoi Danihi⁵; C Ververessou⁵; N Tsogas⁶; C Koutsouri⁸; F Bardaka⁷; F Kalala⁵; C Skoulakis⁸; Aggeliki Rapti²; Mathaios Speletas¹